Additional file 1 of Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy

Additional file 1: Figure S1. Characterisation of ZEGFR:03115-IR700 binding capacity on EGFR-positive GBM cells. Figure S2. Post-PIT DAMPs release. Figure S3. Ability of 18F-AlF-NOTA-ZEGFR:03115 to accumulate in orthotopic U87-MGvIII tumours. Figure S4. In vivo EGFR-targeted PIT in U87-MGvIII subcutaneous tumours. Figure S5. Immune response to PIT.